275 related articles for article (PubMed ID: 33240786)
1. Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art.
Gentile M; Centonza A; Lovero D; Palmirotta R; Porta C; Silvestris F; D'Oronzo S
J Bone Oncol; 2021 Feb; 26():100337. PubMed ID: 33240786
[TBL] [Abstract][Full Text] [Related]
2. The role of biomarkers in the management of bone-homing malignancies.
D'Oronzo S; Brown J; Coleman R
J Bone Oncol; 2017 Nov; 9():1-9. PubMed ID: 28948139
[TBL] [Abstract][Full Text] [Related]
3. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
Stamatopoulos A; Stamatopoulos T; Gamie Z; Kenanidis E; Ribeiro RDC; Rankin KS; Gerrand C; Dalgarno K; Tsiridis E
J Bone Oncol; 2019 Jun; 16():100231. PubMed ID: 30956944
[TBL] [Abstract][Full Text] [Related]
5. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract][Full Text] [Related]
6. Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.
Chai X; Yinwang E; Wang Z; Wang Z; Xue Y; Li B; Zhou H; Zhang W; Wang S; Zhang Y; Li H; Mou H; Sun L; Qu H; Wang F; Zhang Z; Chen T; Ye Z
Front Oncol; 2021; 11():692788. PubMed ID: 34722241
[TBL] [Abstract][Full Text] [Related]
7. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
8. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
9. The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.
Hadji P; Ziller M; Maurer T; Autenrieth M; Muth M; Ruebel A; May C; Birkholz K; Diebel E; Gleissner J; Rothe P; Gschwend JE
J Bone Oncol; 2012 Dec; 1(3):88-94. PubMed ID: 26909262
[TBL] [Abstract][Full Text] [Related]
10. The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.
Hadji P; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Janni W; Muth M; Kreuzeder J; Quiering C; Grischke EM; Tesch H
J Bone Oncol; 2019 Feb; 14():010-10. PubMed ID: 30515367
[TBL] [Abstract][Full Text] [Related]
11. c-Met expression in renal cell carcinoma with bone metastases.
Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
[TBL] [Abstract][Full Text] [Related]
12. Tenascin-C: Form versus function.
Giblin SP; Midwood KS
Cell Adh Migr; 2015; 9(1-2):48-82. PubMed ID: 25482829
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.
Mountzios G; Ramfidis V; Terpos E; Syrigos KN
Clin Lung Cancer; 2011 Nov; 12(6):341-9. PubMed ID: 21703936
[TBL] [Abstract][Full Text] [Related]
15. Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP.
Sarvari BK; Sankara Mahadev D; Rupa S; Mastan SA
Indian J Clin Biochem; 2015 Jan; 30(1):66-71. PubMed ID: 25646043
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
[TBL] [Abstract][Full Text] [Related]
17. Cancer metastases: challenges and opportunities.
Guan X
Acta Pharm Sin B; 2015 Sep; 5(5):402-18. PubMed ID: 26579471
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction.
Ying M; Mao J; Sheng L; Wu H; Bai G; Zhong Z; Pan Z
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240875
[TBL] [Abstract][Full Text] [Related]
19. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.
Berruti A; Dogliotti L; Gorzegno G; Torta M; Tampellini M; Tucci M; Cerutti S; Frezet MM; Stivanello M; Sacchetto G; Angeli A
Clin Chem; 1999 Aug; 45(8 Pt 1):1240-7. PubMed ID: 10430790
[TBL] [Abstract][Full Text] [Related]
20. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
Addison CL; Pond GR; Cochrane B; Zhao H; Chia SK; Levine MN; Clemons M
J Bone Oncol; 2015 Jun; 4(2):47-53. PubMed ID: 26579488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]